US Patent

US11980617 — Methods of treating acute depression and/or acute anxiety

Method of Use · Assigned to Intra Cellular Therapies Inc · Expires 2039-10-27 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating acute depression and/or anxiety by administering a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, such as lumateperone.

USPTO Abstract

The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.

Drugs covered by this patent

lumateperone-tosylate (LUMATEPERONE TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4342`	—	lumateperone-tosylate
`U-4342`	—	lumateperone-tosylate
`U-4342`	—	lumateperone-tosylate

Patent Metadata

Patent number: US11980617
Jurisdiction: US
Classification: Method of Use
Expires: 2039-10-27
Drug substance claim: No
Drug product claim: No
Assignee: Intra Cellular Therapies Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.